What is the recommended treatment for mesial temporal sclerosis?

Treatment for Mesial Temporal Sclerosis

For mesial temporal sclerosis causing drug-resistant epilepsy, anterior temporal lobectomy (ATL) remains the gold-standard surgical treatment with seizure freedom rates of 60-80%, though MR-guided laser interstitial thermal therapy (MRgLITT) offers a minimally invasive alternative with 55-58% seizure freedom rates and significantly lower morbidity. 1

Treatment Algorithm

Step 1: Initial Medical Management

• Begin with antiepileptic drugs (AEDs) as first-line treatment
• Drug-resistant epilepsy (DRE) is defined as failure of 2 adequate trials of appropriately chosen AEDs (whether monotherapy or combination) to achieve sustained seizure freedom 1
• Among AEDs for MTLE-HS, carbamazepine shows the highest retention (85.9%) and seizure freedom rates (11%), followed by valproate (85% retention) 2
• However, long-term medical management alone achieves seizure freedom in only 23% of patients with mesial temporal sclerosis 3

Step 2: Surgical Evaluation Once DRE is Established

After failure of 2 appropriate AED trials, immediately refer for surgical evaluation rather than continuing to cycle through additional medications. The evidence is clear:

Surgical candidates achieve 72% seizure freedom versus 23% with continued medical therapy alone 3

Step 3: Surgical Options (in order of preference based on efficacy)

Option A: Anterior Temporal Lobectomy (ATL) - Gold Standard

• Seizure freedom: 60-80% at 2 years 1
• Proven efficacy in 2 Class I trials
• Hospital stay: 3-4 nights
• This should be your first recommendation for patients who can tolerate open surgery

Option B: Selective Amygdalohippocampectomy (SAH)

• Seizure freedom: 63-88% depending on approach 4, 5
• Trans-anterior T1 approach shows 88% seizure freedom at mean 4.6 years follow-up 4
• Transsylvian approach shows 63.4% complete seizure freedom (Engel Ia) with 88% worthwhile improvement 5
• Lower visual field defect rates (21% contralateral upper quadrantanopia) 4
• Recommend this for patients wanting to minimize lateral temporal neocortex resection

Option C: MR-Guided Laser Interstitial Thermal Therapy (MRgLITT)

• Seizure freedom: 55-58% at 1 year (meta-analysis data) 1
• In the largest multicenter series (234 patients), 58% achieved seizure freedom with 77% showing significant clinical benefit 1
• Hospital stay: 1 night versus 3-4 for ATL
• Significantly lower surgical morbidity and faster recovery
• Choose this for patients who refuse open surgery or prefer minimally invasive approach despite slightly lower seizure freedom rates 1

Critical Decision Points

When to Choose MRgLITT Over ATL:

• Patient refuses open craniotomy
• Patient willing to accept 5-10% lower seizure freedom rate for reduced morbidity
• Need for shorter hospital stay and faster return to activities
• Importantly, many patients now choose MRgLITT when offered both options 1

Contraindications to MRgLITT:

• Inability to identify epileptogenic focus
• Cannot undergo MRI
• Unstable cardiac/respiratory conditions
• Uncontrollable bleeding diathesis 1

Prognostic Factors

Good outcome predictors:

• Early age of seizure onset
• Low number of previously failed AEDs
• Clear concordance on MRI, video-EEG, and semiology 1

Important note: Mesial temporal sclerosis visible on MRI is common but not required if other studies (video-EEG, intracranial EEG) show concordance 1

Mortality Benefit

Surgical treatment normalizes overall mortality even without complete seizure freedom, as long as there is reduction of seizures with impaired awareness 1. This is a critical point—surgery improves survival beyond just seizure control.

Common Pitfalls to Avoid

1. Delaying surgical referral: Surgery remains seriously underutilized despite proven efficacy 6. Refer after 2 failed AED trials, not after years of polypharmacy.

2. Overemphasizing complete seizure freedom: Even significant seizure reduction improves mortality and quality of life 1

3. Not offering MRgLITT: Approximately 90% of patients report satisfaction with their surgical treatment, and many prefer the minimally invasive option when informed 4

4. Assuming newer AEDs are better: No clear advantage of newer versus older AEDs was demonstrated in MTLE-HS 2

Quality of Life Considerations

Post-surgical QOL data shows:

• ~30% report subjective memory decline
• ~50% gain freedom to go out and become employed
• ~90% express satisfaction with surgical treatment 4

The key message: Do not let concerns about invasiveness delay appropriate surgical referral—the mortality and quality of life benefits are substantial, and minimally invasive options now exist.